New combo aims to tame autoimmune anemia without Long-Term steroids
NCT ID NCT07518277
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether adding sirolimus to standard steroid treatment helps people with newly diagnosed mild autoimmune hemolytic anemia (AIHA) achieve lasting remission. About 216 adults will be randomly assigned to get either steroids alone or steroids plus sirolimus for 6 months, then followed for 2 years. The main goal is to see if more people in the combo group can stop steroids and stay in remission at 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking union medical college hospital
Beijing, Shuangfuyuan, NO I., 100730, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus combined with glucocorticoids (steroids)
What this could lead to
If it works, this could offer a way to treat AIHA with fewer steroids and a higher chance of staying in remission without ongoing medication.
What could go wrong
This is an early-stage trial with no phase assigned, so results are uncertain. Sirolimus can cause side effects like infections or metabolic issues, and the benefit over steroids alone may be small.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.